Clinical evaluation of extra-hematologic comorbidity in myelodysplastic syndromes: ready-to-wear versus made-to-measure tool.
作者信息
Della Porta Matteo G, Ambaglio Ilaria, Ubezio Marta, Travaglino Erica, Pascutto Cristiana, Malcovati Luca
出版信息
Haematologica. 2012 Apr;97(4):631-2. doi: 10.3324/haematol.2011.057323. Epub 2012 Jan 22.
Abstract
摘要
相似文献
1
Clinical evaluation of extra-hematologic comorbidity in myelodysplastic syndromes: ready-to-wear versus made-to-measure tool.
Haematologica. 2012 Apr;97(4):631-2. doi: 10.3324/haematol.2011.057323. Epub 2012 Jan 22.
2
Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome.
Haematologica. 2009 May;94(5):602-6. doi: 10.3324/haematol.2009.005702.
3
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.
Haematologica. 2011 Mar;96(3):441-9. doi: 10.3324/haematol.2010.033506. Epub 2010 Dec 6.
4
Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes.
Haematologica. 2011 Oct;96(10):e41-2. doi: 10.3324/haematol.2011.048991.
5
Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes.
Leuk Res. 2015 Aug;39(8):846-52. doi: 10.1016/j.leukres.2015.05.007. Epub 2015 Jun 22.
6
Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment.
Blood Cancer J. 2016 Apr 8;6(4):e414. doi: 10.1038/bcj.2016.23.
7
Management of older adults with myelodysplastic syndromes (MDS).
J Geriatr Oncol. 2018 Jul;9(4):302-307. doi: 10.1016/j.jgo.2017.12.002. Epub 2017 Dec 29.
8
Myelodysplastic syndromes: An analysis of non-hematological prognostic factors and its relationship to age.
J Geriatr Oncol. 2020 Jan;11(1):125-127. doi: 10.1016/j.jgo.2019.06.021. Epub 2019 Jul 11.
9
Combination of Frailty Status and Comorbidity Score Improves the Stratification of Survival in Patients With Myelodysplastic Syndrome Owing to Good Predictive Capability for Infection-related Mortality.
Clin Lymphoma Myeloma Leuk. 2019 Dec;19(12):799-805. doi: 10.1016/j.clml.2019.09.610. Epub 2019 Sep 28.
10
(In)convenience of adding age and comorbidities to prognostic models in myelodysplastic syndromes.
Leukemia. 2018 May;32(5):1264-1266. doi: 10.1038/s41375-018-0064-6. Epub 2018 Feb 22.
本文引用的文献
1
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS).
Haematologica. 2011 Oct;96(10):1433-40. doi: 10.3324/haematol.2011.044602. Epub 2011 Jun 9.
2
Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.
J Clin Oncol. 2011 Jun 1;29(16):2240-6. doi: 10.1200/JCO.2010.31.3353. Epub 2011 May 2.
3
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.
Haematologica. 2011 Mar;96(3):441-9. doi: 10.3324/haematol.2010.033506. Epub 2010 Dec 6.
4
Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.
Leuk Res. 2011 Feb;35(2):159-62. doi: 10.1016/j.leukres.2010.06.005. Epub 2010 Jul 1.
5
Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome.
Haematologica. 2009 May;94(5):602-6. doi: 10.3324/haematol.2009.005702.
6
The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome.
Haematologica. 2009 May;94(5):729-32. doi: 10.3324/haematol.2008.002063. Epub 2009 Mar 31.
7
Comorbid disease and cancer: the need for more relevant conceptual models in health services research.
J Clin Oncol. 2005 Oct 20;23(30):7399-404. doi: 10.1200/JCO.2004.00.9753.
8
Prognostic importance of comorbidity in a hospital-based cancer registry.
JAMA. 2004 May 26;291(20):2441-7. doi: 10.1001/jama.291.20.2441.
9
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8.
Zotero 插件